Corpus ID: 91432454

Propagermanium Reduces Atherosclerosis in Apolipoprotein E Knockout Mice via Inhibition of Macrophage Infiltration

@inproceedings{TomoyaYamashita2002PropagermaniumRA,
  title={Propagermanium Reduces Atherosclerosis in Apolipoprotein E Knockout Mice via Inhibition of Macrophage Infiltration},
  author={TomoyaYamashita and SeinosukeKawashima and Masanoriozaki and MasayukiNamiki and NobutakaInoue and Ken-ichiHirata and MitsuhiroYokoyama},
  year={2002}
}
Monocyte chemoattractant protein-1 (MCP-1), which binds to C-C chemokine receptor 2, has been implicated as the primary source of monocyte chemoattractant function in the early stages of atherosclerosis. Recently, propagermanium, a drug used clinically for the treatment of chronic hepatitis in Japan, has been shown to inhibit C-C chemokine receptor 2 function and suppress monocyte/macrophage infiltration in vitro and in vivo. Given the importance of monocyte infiltration in atherogenesis, the… Expand
3 Citations